Search clinical trials for: IN10018（Ifebemtinib）

Total 32 results

InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
InventisBio Co., Ltd
InxMed (Shanghai) Co., Ltd.

Recruiting

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Solid Tumor

China
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent

China
Renovo

Completed

Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects

Cicatrix

United Kingdom
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
InxMed (Shanghai) Co., Ltd.

Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Gastric Cancer

China
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
Renovo

Completed

Juvista in Scar Revision Surgery of Disfiguring Scars (Revise)

Cicatrix

Spain, France, Hungary, Italy, United Kingdom, United States, Denmark, Germany, Latvia, Poland
Cangene Corporation

Withdrawn

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Hemophilia B

United Kingdom, United States
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

NSCLC

China
Renovo

Completed

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing | Re-epithelialization

United Kingdom
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Metastatic Melanoma

United States, Australia
iN Therapeutics Co., Ltd.

Completed

A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers

Pain | Osteoarthritis

Australia
Renovo

Completed

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

Cicatrix | Wound Healing

United Kingdom
Renovo

Completed

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing

United Kingdom
Medexus Pharma, Inc.

Completed

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Hemophilia B

United States, France, United Kingdom, India, Israel, Italy, Poland
Renovo

Completed

A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo (RN1006)

Scar Improvement

United Kingdom
Renovo

Completed

Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects

Cicatrix | Wound Healing

United Kingdom
IntraBio Inc

Completed

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

GM2 Gangliosidosis | Tay-Sachs Disease | Sandhoff Disease

United States, Germany, Spain, United Kingdom
Renovo

Completed

Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males

Cicatrix

United Kingdom
InxMed (Shanghai) Co., Ltd.

Not yet recruiting

IN10018 Combination Therapy in Previously-treated Solid Tumors

Solid Tumor
IntraBio Inc

Recruiting

N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Ataxia Telangiectasia | Louis Bar Syndrome

Spain, United States, Germany, United Kingdom
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Small Cell Lung Cancer Extensive Stage

China
IntraBio Inc

Completed

N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

Niemann-Pick Disease, Type C

United States, United Kingdom, Germany, Slovakia, Spain
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Herpes Zoster
IntraBio Inc

Active, not recruiting

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Niemann-Pick Disease, Type C

United States, Australia, United Kingdom, Germany, Slovakia, Netherlands, Czechia, Switzerland
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Renovo

Completed

Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women

Cicatrix

United Kingdom
Renovo

Completed

Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions

Cicatrix

United Kingdom

3

Subscribe